Additionally, in the gefitinib group, PFS in the mutation-negative subgroup was shorter than that of the mutation-positive group (with a median of 2.1 vs. 8.4 months). There was no difference between these two subgroups in the chemotherapy group.
"Gefitinib did not improve overall survival over the standard chemotherapy," said Jin S. Lee, M.D. of the National Cancer Center Korea in Goyang, Korea. "However, a promising survival outcome along with high overall response rate and better toxicity profile suggests that gefitinib might be a reasonable first-line therapy for this group of never-smoker lung cancer patients."
Dr. Lee will present this study on Monday, August 3 at 9:35 am PT in Moscone West, Ballroom, Level 3.
EFFICIENCY OF MAINTENANCE ERLOTINIB VERSUS PLACEBO IN PATIENTS WITH UNRESECTABLE STAGE III NON-SMALL LUNG CANCER (NSCLC) FOLLOWING CONCURRENT CHEMORADIATION (D0410, NCT00153803) (ABSTRACT # C6.1)
Currently, the role of maintenance therapy following concurrent treatment with chemotherapy and radiotherapy (cCRT) in patients with unresectable stage III non-small lung cancer (NSCLC) remains undefined, and concern has been noted with maintenance therapies. To examine alternative treatment options, this trial was designed to evaluate the effectiveness of maintenance erlotinib following cCRT in unresectable stage III NSCLC patients.
In this upfront, randomized, placebo-controlled phase III trial, scientists randomly assigned 243 patients with unresectable stage III NSCLC to receive erlotinib or placebo daily following their cCRT.
In the intent-to-treat analysis, there was no statistically significant difference in the primary endpoint of progression-free survival (PF
|Contact: Liz Wulderk|
International Association for the Study of Lung Cancer